Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder?

Published in: International urology and nephrology (2018)

Advanced CKD showed a trend of declining sclerostin levels and significantly higher CIMT levels. Serum sclerostin was not associated with CIMT. More studies are needed in order to reveal the exact role of sclerostin in the complexity of CKD-MBD pathophysiological mechanism.

Keyphrases

chronic kidney disease
cardiovascular disease
bone mineral density
genome wide
gene expression
type diabetes
single cell
density functional theory
dna methylation
bone regeneration